Evidence map›Paper›PMID 23558043›Full record

Trial reportThe American journal of cardiology2013

Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.

Angelo Villano, Antonino Di Franco, Roberto Nerla, Alfonso Sestito, Pierpaolo Tarzia, Priscilla Lamendola, Antonio Di Monaco, Filippo Maria Sarullo, Gaetano Antonio Lanza, Filippo Crea

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The American journal of cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02910154 (Comprehensive Treatment of Angina in Women With Microvascular Dysfunction - a Proof of Concept Study of the iPower Cohort), which is not on this map. Cited by 88 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02910154 nacompletedstarted 2016, after this paper: background citation

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction - a Proof of Concept Study of the iPower Cohort

Ran2016Enrolled62Registered outcomes9Posted comparisons0ConditionsAngina Pectoris, Coronary Microvascular DiseaseArmsdiet, Medication (with statin and ACE-inhibition), training
PMID 19878986PMID 23432189PMID 10675425PMID 11788217PMID 11991214PMID 12147179PMID 12914662PMID 13394341PMID 15007010PMID 15020531PMID 15671433PMID 16368303other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. A systematic review of enrolment criteria and treatment efficacy for microvascular angina.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Ranolazine for stable angina pectoris.The Cochrane database of systematic reviews · 2017
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Contemporary Antianginal Therapy.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Review
  18. Article
  19. Article
  20. Current Evidence-Based Treatment of Angina With Nonobstructive Coronary Arteries (ANOCA).Journal of the Society for Cardiovascular Angiography & Interventions · 2025
    Review

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Angelo VillanoDepartment of Cardiovascular Medicine, Università Cattolica del Sacro Cuore, Roma, Italy.
Antonino Di Franco
Roberto Nerla
Alfonso Sestito
Pierpaolo Tarzia
Priscilla Lamendola
Antonio Di Monaco
Filippo Maria Sarullo
Gaetano Antonio Lanza
Filippo Crea

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with microvascular angina (MVA) often have persistence of symptoms despite full classical anti-ischemic therapy. In this study, we assessed the effect of ivabradine and ranolazine in MVA patients. We randomized 46 patients with stable MVA (effort angina, positive exercise stress test [EST], normal coronary angiography, coronary flow reserve <2.5), who had symptoms inadequately controlled by standard anti-ischemic therapy, to ivabradine (5 mg twice daily), ranolazine (375 mg twice daily), or placebo for 4 weeks. The Seattle Angina Questionnaire (SAQ), EuroQoL scale, and EST were assessed at baseline and after treatment. Coronary microvascular dilation in response to adenosine and to cold pressor test and peripheral endothelial function (by flow-mediated dilation) were also assessed. Both drugs improved SAQ items and EuroQoL scale compared with placebo (p <0.01 for all), with ranolazine showing some more significant effects compared with ivabradine, on some SAQ items and EuroQoL scale (p <0.05). Time to 1-mm ST-segment depression and EST duration were improved by ranolazine compared with placebo. No effects on coronary microvascular function and on flow-mediated dilation were observed with drugs or placebo. In conclusion, ranolazine and ivabradine may have a therapeutic role in MVA patients with inadequate control of symptoms in combination with usual anti-ischemic therapy.

Indexed as

AcetanilidesAnalysis of VarianceAngina PectorisBenzazepinesChi-Square DistributionCoronary AngiographyEnzyme InhibitorsExercise TestFemaleHumansIvabradineMaleMiddle AgedPiperazinesPlacebosQuality of LifeAcetanilidesBenzazepinesEnzyme InhibitorsIvabradinePiperazinesPlacebosRanolazine

Identifiers

PMID23558043

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.